CompletedPhase 4NCT03201770
Cohort Event Monitoring Study of Pyramax®
Studying Malaria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
- Principal Investigator
- Michael Ramharter, MD, DTM&HCERMEL, University of Tübingen, Germany
- Intervention
- pyronaridine artesunate(drug)
- Enrollment
- 8572 target
- Eligibility
- All sexes
- Timeline
- 2017 – 2019
Study locations (5)
- The Biotechnology Center Nkolbisson, Univ of Yaounde I, Messa, Yaoundé, Cameroon
- Institut Pierre Richet / Institut National de SanPublique (IPR/INSP), Bouaké, Côte d’Ivoire
- Centre de Recherche du Centre Hospitalier du Mont Amba, Kinshasa, Democratic Republic of the Congo
- CERMEL, Albert Schweitzer Hospital, Lambaréné, Gabon
- Centre de Santé FCRM, Hospital of Talangai, Brazzaville, Republic of the Congo
Collaborators
Medicines for Malaria Venture
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03201770 on ClinicalTrials.govOther trials for Malaria
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07257965Clinical Study to Assess Minimum Mosquito Bites for P. Vivax Infection in Thai AdultsUniversity of Oxford
- RECRUITINGPHASE2NCT07147400Pfs230D1 + R21 in Matrix-M1 in African School Children and AdultsSerum Institute of India Pvt. Ltd.
- RECRUITINGPHASE2NCT07036159A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 MonthsGlaxoSmithKline
- ACTIVE NOT RECRUITINGPHASE1NCT06735209First-in-Human PfSPZ-LARC2 Vaccination/CHMINational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGPHASE2NCT07060508L9LS in Women of Childbearing Potential in MaliNational Institute of Allergy and Infectious Diseases (NIAID)
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06549257Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45/48 Administered Alone and in Combination, in Matrix-M AdjuvantUniversity of Oxford
- ACTIVE NOT RECRUITINGNANCT06599593Leveraging the Seasonal Malaria Chemoprevention Platform to Address Malaria and MalnutritionUniversity of California, San Francisco
- RECRUITINGPHASE4NCT07038837Comparison of Two Strategies for Administering the R21-Matrix M Vaccine in a Context of Seasonal Malaria Transmission in ChadEpicentre